AstraZeneca's Lokelma To Join Veltassa In Hyperkalemia Sector

 
• By John Davis

The treatment of hyperkalemia in Europe in patients with chronic kidney disease or chronic heart failure looks set to become more vibrant, with AstraZeneca's Lokelma likely to join Vifor Pharma's Veltassa in the marketplace.

Racing
Competition may increase in the hyperkalemia sector • Source: Shutterstock

More from Genitourinary

More from Therapy Areas